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Introduction
F
or  a  DNA  virus,  the  HBV  genome  shows 
an exceptional degree of molecular variation 
(incorporation  of  some  1010  mistaken  nucleotides 
into the HBV virion per day (1). Over time, HBV’s 
spontaneous  tendency  for  mutations  has  led  to 
the  emergence  of  at  least  eight  HBV  genotypes 
(designated A to H), defined by a divergence of 8% 
or more with reference to the complete nucleotide 
sequence  (2).  These  different  genotypes  show  a 
distinct geographic distribution: genotype A is found 
in northern Europe, the United States, and Central 
Africa; B and C predominate in Asia; D is associated 
with southern Europe, the Middle East, and India; 
E is uniquely African; and F is found in Central and 
South America as well as in Polynesia (3, 4). Genotype 
G has recently been localized in the United States and 
France (5), whereas a putative eighth genotype H has 
also been discovered in Central America (6). Turkey 
has  been  found  to  be  an  intermediate-endemic 
region (2% - 7%), with about 6,500 individuals who 
are newly infected by HBV per year (7, 8). Previous 
studies  have  verified  the  dominance  of  genotype 
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Background and Aims: Previous studies have demonstrated the dominance of genotype D subtype ayw in patients with 
hepatitis B virus infection in Turkey. The aim of the present study is to report, for the first time, genotype A2 subtype 
adw2 of hepatitis B virus in a patient who is an inactive hepatitis B carrier in Turkey. 
Materials and Methods: Hepatitis B virus DNA isolated from the serum sample was amplified by polymerase chain reaction. 
The polymerase gene segment of the hepatitis B virus was directly sequenced. A distance matrix/UPGMA comparison was 
used for phylogenetic analysis, and the genotype of the virus was identified accordingly. The subgenotype and subtype 
of hepatitis B virus were also detected. 
Results: The genotyping of the patient revealed that the isolated hepatitis B virus was genotype A2/adw2. 
Discussion: The subtype is inconsistent with the previous data from Turkey; specifically, the identification of the A2/adw2   
subtype of the hepatitis B virus in an inactive carrier is the first such case in Turkey. This finding suggests that the 
transmission of another genotype besides genotype D subtype ayw of the hepatitis B virus is possible in Turkey.
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D subtype ayw in patients with HBV infection in 
Turkey (7, 9-12). The aim of the present study is to 
report, for the first time, that the genotype A2/adw2 
of HBV can exist in an inactive hepatitis B carrier 
patient in Turkey. 
Case Presentation
The  patient’s  condition  was  detected  in  a 
routine screening  for  amino-acid  substitutions  for 
nucleos(t)ide  analogues  in  treatment-naive  HBV 
patients with chronic infection. A 20-year-old male 
Turkish  patient  with  a  significant  medical  history 
of  nephrotic  syndrome  and  a  history  of  blood 
transfusion during his childhood was admitted to 
the hospital. The patient had also been treated for 
membranous glomerulonephritis in childhood. Following 
a  blood  transfusion,  the  patient  had  developed 
hepatitis, nausea, lack of appetite, high Transaminase 
levels (ALT = 1216 U/L, AST = 903 U/L), and high 
Bilirubin levels (BU = 9,5 mg/dl, BC = 4,9 mg/dl). 
Hepatitis B surface antigen (HBsAg), anti-HBcAg 
total  antibody  (anti-HBcIgG),  and  anti-HBeAg 
antibody (anti-HBe) were later found to be positive. 
The patient was seronegative for hepatitis A and C 
viruses. 
Because previous serum samples were not available 
for analysis, the data could not be included in this 
study (and also the lack of data allowed the patient’s 
condition to change, developing spontaneous HBeAg 
seroconversion).  This case was characterized by HBsAg 
(+), anti-HBcIgG (+), HBeAg (-), anti-HBe (+) very 
low HBV DNA load (102 IU/ml), anti-HAV IgG 
(+), and anti-HAV IgM (-); seronegativity for HDV, 
HCV, and HIV; normal transaminase levels (ALT = 
14 U/L, AST = 19 U/L); and autoantibody negativity 
(antinuclear, antimitochondrial, antidoublestranded 
DNA,  and  antismooth  muscle  antibodies).  The 
patient  had  undergone  clinical  evaluation  two 
times in the last year and had been evaluated as an 
inactive hepatitis B carrier according to the EASL 
clinical practice guidelines (13). Serological markers 
for HBV were tested using a commercially available 
microparticle  enzyme  immunoassay  kit  (AxSym, 
Abbott Laboratories, IL, USA). On the other hand, 
his family members tested negative seronegative for 
HBV, and the patient reported that he did not travel 
abroad,  use  intravenous  drugs,  or  have  high  risk 
sexual contact to date.
Materials And Methods
HBV DNA was isolated from the serum sample 
on  the  biorobot  workstation  using  magnetic-
particle  technology  (NucliSENS,  easyMAG, 
bioMérieux,  Boxtel,  Holland).  HBV  DNA  was 
detected  and  quantified  by  a  commercial  PCR 
assay  (Iontek  Biyotechnology  Inc,  Istanbul, 
Turkey)  on  the  real-time  platform  (iCycler  iQ5, 
Bio  Rad  Laboratories  Inc.,  California,  USA). 
Briefly, a pair of primers was designed (forward = 
5'-TCGTGGTGGACTTCTCTCAATT-3'  and 
reverse = 5'-GTTGACAGACTTTCCAATCAAT-3') 
for amplification of the HBV polymerase region. The 
PCR conditions for the polymerase gene segment 
were as follows: 95°C for 15 min, 45 cycles consisting 
of 95°C for 45 sec., 56°C for 45 sec., and 72°C for 
45 sec. The final concentration of the primer pairs 
was 0.3 μM. The size of the amplicon of the HBV 
was around 742-bp. The PCR product was purified 
using the High Pure PCR Product Purification Kit® 
(Roche Diagnostics GmbH, Mannheim, Germany) 
and directly sequenced with the ABI PRISM 310 
Genetic Analyzer® equipment using the DYEnamic 
ET Terminator Cycle Sequencing Kit® (Amersham 
Pharmacia Biotech Inc, Piscataway, NJ, USA). For 
cycle sequencing, the following thermal protocol was 
used: 35 cycles consisting of 95°C for 20 sec., 50°C 
for 25 sec., and finally 60°C for 2 min. The reverse 
primer was used as the sequencing primer at a final 
concentration of 0.5 uM. The electropherogram was 
assembled using Vector NTI® v5.1 (InforMaxTM 
InvitrogenTM life science software, Frederick, MD, 
USA).
The  HBV  genotype  was  determined  by  a 
phylogenetic analysis. The nucleotide sequence was 
compared to those from the international DNA data 
bank  (DDBJ/EMBL/GenBank). The  phylogenetic 
comparison  was  performed  by  a  distance  matrix/
UPGMA analysis using the Kimura 2-parameter via 
MEGA2 software package program (Figure 1) (14). 
However, the HBV genotype was also determined 
with the genotyping tools of the National Center for 
Biotechnology  Information  (NCBI,  U.S  National 
Library of Medicine, Bethesda, MD, USA, http://
www.ncbi.nih.gov/projects/genotyping),  the 
International Repository for Hepatitis B Virus Strain 
Data  (HepSEQ,  http://www.hpa-bioinfodatabases.
org.uk),  and  the  Oxford  HBV  subtype  tool 
(http://www.bioafrica.net/rega-genotype/html/
subtypinghbv.html).  The  subgenotype  of  the 
virus  was  determined  as  A2  by  the  Genafor/
Arevir geno2pheno drug resistance tool (Center of 
Advanced  European  Studies  and  Research,  Bonn, 
Germany, http://coreceptor.bioinf.mpi-inf.mpg.de). 
The genotyping and subgenotyping tools work by 
using BLAST to compare a query sequence to a set 
of reference sequences for known genotypes.Hepat Mon. 2010; 10(4): 302-305
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Results
The  HBV  strain  was  genotyped  as  A/adw2 
(GenBank  accession  number  GU726170) 
using  phylogenetic  analysis  and  genotyping  and 
subgenotyping  tools  as  described  above.  The 
similarity of the strain to the subgenotype profile was 
98.35% and was therefore subgenotyped as A2.
Discussion
This  case  report  demonstrates  the  first 
identification  of  the  genotype  A2/adw2  of  HBV 
in an inactive hepatitis B carrier patient in Turkey. 
This infection may have been caused by the patient’s 
childhood blood transfusion; it is possible that this 
may not have been clearly detected via serological 
methods  during  the  donation  of  the  transfused 
blood. Several studies have shown that genotype D of 
HBV is present in almost the entire Turkish patient 
population infected with HBV (9-12, 15). According 
to a restriction fragment length polymorphism study, 
genotype D with a D2 pattern is the dominant HBV 
genotype  in  all  age  groups  in Turkey  (16).  It  was 
recently reported that genotype D is still predominant 
among Turkish patients with chronic HBV infection 
(17, 18). The analysis of S-gene amino-acid sequences 
revealed that the surface-gene subtypes of Turkish 
patients  with  chronic  HBV  infection  were  ayw2 
and ayw3 (7). In another study with a large cohort 
of  Turkish  patients  with  chronic  HBV  infection, 
HBsAg subtyping revealed that 99% of the patients 
were subtype ayw2 (9).
Genotyping of HBV is commonly detected by 
direct sequencing and phylogenetic tree analysis (7, 9).   
However, phylogenetic analysis is time consuming 
for a large number of clinical samples. In our case 
study, the results were similar for the phylogenetic 
tree and genotyping tools. Genotyping of HBV on 
the software programs, such as NCBI, geno2pheno, 
or  HepSEQ  genotyping  tools  is  a  convenient 
approach.
Genotyping of HBV has become of great interest 
as reports indicate that there are differences in the 
clinical  outcome  of  infection  by  genotype  and 
differences in response to treatment. For instance, 
HBV genotypes A and B have been shown to be 
associated with a better response to interferon alpha 
than genotypes C and D. However, HBV genotype 
does not influence the response to any nucleos(t)ide 
analogues (13).
In conclusion, our case is the first case in which 
the genotype A2/adw2 of HBV was detected, and 
Figure 1. Phylogenetic tree obtained by distance matrix/UPGMA comparison (with Kimura-2 
correction) after bootstrapping 1000 replicates of sequence segment at amino acid positions 
between 80-250 from the reverse transcriptase domain of the polymerase region of hepatitis 
B virus (UA20 is our patient, the others are from the gene bank)Hepat Mon. 2010; 10(4): 302-305
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this is not consistent with previous data from Turkey. 
This finding suggests that transmission of another 
genotype, except genotype D subtype ayw of HBV, 
is possible in Turkey.
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